Alethia Biotherapeutics Inc
Alethia Biotherapeutics Inc, based in Montréal, QC, is focused on developing innovative cancer therapies, particularly targeting epithelial to mesenchymal transition (EMT) to combat chemotherapy resistance and metastatic tumor invasion. Their lead product, AB16B5, is a humanized IgG2 monoclonal antibody designed to inhibit EMT, showing promising preclinical results in enhancing chemotherapy response and reducing tumor invasion.
The company has received FDA authorization to initiate Phase 2 development for AB16B5, marking a significant milestone in its research efforts. Alethia Biotherapeutics is set to present its findings at the Annual ASCO Meeting, highlighting the potential of their EMT inhibitor in treating metastatic non-small cell lung cancer.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.